In this issue:
Nivolumab-based front-line therapy for cHL
Health-related quality of life in patients with HL
Early evidence of pulmonary dysfunction in survivors of childhood HL
Long-term outcomes of patients with unfavourable cHL treated with the Stanford V regimen
Primary therapy and relative survival in cHL
Loss of nivolumab binding to T cell PD-1 predicts relapse of HL
Stage I-II nodular lymphocytepredominant HL
Nivolumab for relapsed or refractory HL
Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL
Please login below to download this issue (PDF)